STOCK TITAN

[Form 4] Health Catalyst, Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Health Catalyst, Inc. (HCAT) reporting officer Jason Alger, the company's Chief Financial Officer, reported a mandatory sale of common stock to satisfy tax withholding from vested restricted stock units. The Form 4 shows a disposition of 2,613 shares on 09/02/2025 at a reported price of $3.3627 per share, leaving the reporting person with 267,033 shares beneficially owned after the transaction. The filing was submitted as an individual Form 4 and signed on behalf of the reporting person by an attorney-in-fact on 09/04/2025. The filing clarifies this was a non-discretionary "sell to cover" required by the issuer's equity plan and not an independent trading decision.

Jason Alger, Chief Financial Officer di Health Catalyst, Inc. (HCAT) e soggetto segnalante, ha dichiarato una vendita obbligatoria di azioni ordinarie per soddisfare le ritenute fiscali su unità azionarie soggette a vesting. Il Modulo 4 indica una cessione di 2.613 azioni in data 02/09/2025 al prezzo riportato di $3,3627 per azione, lasciando il soggetto segnalante con 267.033 azioni detenute in via beneficiaria dopo la transazione. La comunicazione è stata presentata come Modulo 4 individuale e firmata per conto del soggetto segnalante da un procuratore il 04/09/2025. Il documento specifica che si è trattato di una vendita non discrezionale "sell to cover" richiesta dal piano azionario dell'emittente e non di una decisione di negoziazione autonoma.

Jason Alger, Director Financiero (CFO) de Health Catalyst, Inc. (HCAT) y persona informante, declaró una venta obligatoria de acciones ordinarias para cubrir las retenciones fiscales de unidades restringidas que han adquirido derechos. El Formulario 4 muestra una disposición de 2.613 acciones el 02/09/2025 a un precio informado de $3.3627 por acción, dejando a la persona informante con 267.033 acciones en propiedad beneficiaria tras la operación. La presentación se realizó como un Formulario 4 individual y fue firmado en nombre de la persona informante por un apoderado el 04/09/2025. El documento aclara que fue una "sell to cover" no discrecional exigida por el plan de acciones del emisor y no una decisión de negociación independiente.

Health Catalyst, Inc. (HCAT)의 보고의무자이자 최고재무책임자(CFO)인 제이슨 알저(Jason Alger)는 베스팅된 제한주식단위의 세금 원천징수를 충당하기 위해 의무적인 보통주 매각을 보고했습니다. Form 4에는 2025-09-02에 주당 $3.3627의 신고 가격으로 2,613주가 처분된 것으로 기재되어 있으며, 거래 후 보고의무자가 실질적으로 보유한 주식 수는 267,033주로 남습니다. 신고서는 개인 Form 4로 제출되었고 2025-09-04에 대리인이 보고의무자를 대신하여 서명했습니다. 해당 서류는 발행사의 주식 계획에 따라 요구된 비재량적 'sell to cover'로서 독립적인 거래 결정이 아님을 명확히 하고 있습니다.

Jason Alger, directeur financier (CFO) de Health Catalyst, Inc. (HCAT) et personne déclarante, a signalé une vente obligatoire d'actions ordinaires pour couvrir les retenues fiscales sur des unités d'actions restreintes arrivées à vesting. Le formulaire 4 indique une cession de 2 613 actions le 02/09/2025 au prix déclaré de 3,3627 $ par action, laissant la personne déclarante avec 267 033 actions détenues à titre bénéficiaire après la transaction. Le dépôt a été effectué en tant que formulaire 4 individuel et signé pour le compte de la personne déclarante par un mandataire le 04/09/2025. Le dossier précise qu'il s'agissait d'une opération non discrétionnaire de type « sell to cover » exigée par le plan d'actions de l'émetteur et non d'une décision de négociation indépendante.

Jason Alger, Finanzvorstand (CFO) von Health Catalyst, Inc. (HCAT) und meldepflichtige Person, meldete einen verpflichtenden Verkauf von Stammaktien zur Begleichung der Steuerabzüge auf gewordene Restricted Stock Units. Aus dem Formular 4 geht hervor, dass am 02.09.2025 insgesamt 2.613 Aktien zu einem angegebenen Preis von $3,3627 pro Aktie veräußert wurden, wodurch die meldepflichtige Person nach der Transaktion 267.033 wirtschaftlich gehaltene Aktien verbleiben. Die Meldung wurde als individuelles Formular 4 eingereicht und am 04.09.2025 von einem Bevollmächtigten im Namen der meldepflichtigen Person unterzeichnet. Die Einreichung stellt klar, dass es sich um einen nicht diskretionären "sell to cover" handelte, der durch den Aktienplan des Emittenten vorgeschrieben ist, und nicht um eine eigenständige Handelsentscheidung.

Positive
  • Transaction was non-discretionary and executed solely to satisfy tax withholding obligations from RSU vesting
  • Reporting person retains substantial ownership after the transaction: 267,033 shares beneficially owned
Negative
  • Disposition of 2,613 shares on 09/02/2025 at $3.3627 per share reduced direct holdings
  • Form does not disclose additional context such as total RSUs vested or aggregate value of the transaction beyond per-share price and share count

Insights

TL;DR: Routine, non-discretionary insider tax-related sale; governance practices enforced by issuer equity plan.

The Form 4 documents a standard "sell to cover" transaction tied to RSU vesting rather than a voluntary sale, indicating the company enforces tax-withholding through mandatory share disposition. Such mechanics are common in equity compensation administration and typically do not signal change in insider sentiment. The remaining beneficial ownership of 267,033 shares suggests continued alignment with shareholders, though the filing does not disclose exercise dates or additional compensation details.

TL;DR: Small, administrative disposal; minimal market impact given size and context.

The reported disposition of 2,613 shares at $3.3627 was explicitly to cover tax obligations from vested RSUs. The transaction size is small relative to the total beneficial holdings reported, so it is unlikely to be material to valuation or signal a change in the officer's investment posture. No options, derivative transactions, or additional disposals are reported in this filing.

Jason Alger, Chief Financial Officer di Health Catalyst, Inc. (HCAT) e soggetto segnalante, ha dichiarato una vendita obbligatoria di azioni ordinarie per soddisfare le ritenute fiscali su unità azionarie soggette a vesting. Il Modulo 4 indica una cessione di 2.613 azioni in data 02/09/2025 al prezzo riportato di $3,3627 per azione, lasciando il soggetto segnalante con 267.033 azioni detenute in via beneficiaria dopo la transazione. La comunicazione è stata presentata come Modulo 4 individuale e firmata per conto del soggetto segnalante da un procuratore il 04/09/2025. Il documento specifica che si è trattato di una vendita non discrezionale "sell to cover" richiesta dal piano azionario dell'emittente e non di una decisione di negoziazione autonoma.

Jason Alger, Director Financiero (CFO) de Health Catalyst, Inc. (HCAT) y persona informante, declaró una venta obligatoria de acciones ordinarias para cubrir las retenciones fiscales de unidades restringidas que han adquirido derechos. El Formulario 4 muestra una disposición de 2.613 acciones el 02/09/2025 a un precio informado de $3.3627 por acción, dejando a la persona informante con 267.033 acciones en propiedad beneficiaria tras la operación. La presentación se realizó como un Formulario 4 individual y fue firmado en nombre de la persona informante por un apoderado el 04/09/2025. El documento aclara que fue una "sell to cover" no discrecional exigida por el plan de acciones del emisor y no una decisión de negociación independiente.

Health Catalyst, Inc. (HCAT)의 보고의무자이자 최고재무책임자(CFO)인 제이슨 알저(Jason Alger)는 베스팅된 제한주식단위의 세금 원천징수를 충당하기 위해 의무적인 보통주 매각을 보고했습니다. Form 4에는 2025-09-02에 주당 $3.3627의 신고 가격으로 2,613주가 처분된 것으로 기재되어 있으며, 거래 후 보고의무자가 실질적으로 보유한 주식 수는 267,033주로 남습니다. 신고서는 개인 Form 4로 제출되었고 2025-09-04에 대리인이 보고의무자를 대신하여 서명했습니다. 해당 서류는 발행사의 주식 계획에 따라 요구된 비재량적 'sell to cover'로서 독립적인 거래 결정이 아님을 명확히 하고 있습니다.

Jason Alger, directeur financier (CFO) de Health Catalyst, Inc. (HCAT) et personne déclarante, a signalé une vente obligatoire d'actions ordinaires pour couvrir les retenues fiscales sur des unités d'actions restreintes arrivées à vesting. Le formulaire 4 indique une cession de 2 613 actions le 02/09/2025 au prix déclaré de 3,3627 $ par action, laissant la personne déclarante avec 267 033 actions détenues à titre bénéficiaire après la transaction. Le dépôt a été effectué en tant que formulaire 4 individuel et signé pour le compte de la personne déclarante par un mandataire le 04/09/2025. Le dossier précise qu'il s'agissait d'une opération non discrétionnaire de type « sell to cover » exigée par le plan d'actions de l'émetteur et non d'une décision de négociation indépendante.

Jason Alger, Finanzvorstand (CFO) von Health Catalyst, Inc. (HCAT) und meldepflichtige Person, meldete einen verpflichtenden Verkauf von Stammaktien zur Begleichung der Steuerabzüge auf gewordene Restricted Stock Units. Aus dem Formular 4 geht hervor, dass am 02.09.2025 insgesamt 2.613 Aktien zu einem angegebenen Preis von $3,3627 pro Aktie veräußert wurden, wodurch die meldepflichtige Person nach der Transaktion 267.033 wirtschaftlich gehaltene Aktien verbleiben. Die Meldung wurde als individuelles Formular 4 eingereicht und am 04.09.2025 von einem Bevollmächtigten im Namen der meldepflichtigen Person unterzeichnet. Die Einreichung stellt klar, dass es sich um einen nicht diskretionären "sell to cover" handelte, der durch den Aktienplan des Emittenten vorgeschrieben ist, und nicht um eine eigenständige Handelsentscheidung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Alger Jason

(Last) (First) (Middle)
C/O HEALTH CATALYST, INC.
10897 SOUTH RIVER FRONT PARKWAY, #300

(Street)
SOUTH JORDAN UT 84095

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Health Catalyst, Inc. [ HCAT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/02/2025 F(1) 2,613 D $3.3627 267,033 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Issuer's Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Remarks:
/s/Benjamin Landry, as Attorney-in-Fact 09/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did HCAT CFO Jason Alger report on Form 4?

He reported a sale of 2,613 shares on 09/02/2025 at $3.3627 per share to cover tax withholding from vested RSUs.

Was the sale by Jason Alger discretionary or mandated?

The filing states the sale was a mandated "sell to cover" under the issuer's equity incentive plan, not a discretionary trade.

How many HCAT shares does the reporting person own after the transaction?

The Form 4 reports 267,033 shares beneficially owned following the reported disposition.

When was the Form 4 filed and who signed it?

The form indicates the transaction date of 09/02/2025 and was signed by an attorney-in-fact on 09/04/2025.

Does the filing report any derivative securities or options?

No. Table II for derivative securities contains no reported transactions in this filing.
Health Catalyst

NASDAQ:HCAT

HCAT Rankings

HCAT Latest News

HCAT Latest SEC Filings

HCAT Stock Data

232.23M
66.98M
3.45%
79.75%
5.55%
Health Information Services
Services-computer Programming, Data Processing, Etc.
Link
United States
SOUTH JORDAN